Emerging pharmacologic therapies for osteoporosis

• CUMMINGS SR, MELTON LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 359(9319):1761-1767.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, BLACK DM, RUBIN SM: Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch. Intern. Med. (1989) 149(11):2445-2448.
   PubMed Web of Science ®Google Scholar
• SAMBROOK P, COOPER C: Osteoporosis. Lancet (2006) 367(9527):2010-2018.
   PubMed Web of Science ®Google Scholar
• KHOSLA S: Minireview: the OPG/RANKL/RANK system. Endocrinology (2001) 142(12):5050-5055.
   PubMed Web of Science ®Google Scholar
• ZHAO C, IRIE N, TAKADA Y et al.: Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. (2006) 4(2):111-121.
   PubMed Web of Science ®Google Scholar
• KARSDAL MA, MARTIN TJ, BOLLERSLEV J, CHRISTIANSEN C, HENRIKSEN K: Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res. (2007) 22(4):487-494.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23(4):517-523.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, WELLS G, WILLAN A et al.: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. (2002) 23(4):508-516.
   PubMed Web of Science ®Google Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
   PubMed Web of Science ®Google Scholar
• THE WOMEN'S HEALTH INITIATIVE STEERING COMMITTEE: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women'S Health Initiative randomized controlled trial. JAMA (2004) 291(14):1701-1712.
   PubMed Web of Science ®Google Scholar
• NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1 – 34) on fracturesand bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344(19):1434-1441.
   PubMed Web of Science ®Google Scholar
• BLOUIN J, DRAGOMIR A, STE-MARIE L-G, FERNANDES JC, PERREAULT S: Discontinuation of antiresorptive therapies: a comparison between 1998 – 2001 and 2002 – 2004 among osteoporotic women. J. Clin. Endocrinol. Metab. (2007) 92(3):887-894.
   PubMed Web of Science ®Google Scholar
• PAPAIOANNOU A, IOANNIDIS G, ADACHI JD et al.: Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int. (2003) 14(10):808-813.
   PubMed Web of Science ®Google Scholar
• TOSTESON ANA, GROVE MR, HAMMOND CS et al.: Early discontinuation of treatment for osteoporosis. Am. J. Med. (2003) 115(3):209-216.
   PubMed Web of Science ®Google Scholar
• SEEMAN E, COMPSTON J, ADACHI J et al.: Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. (2007) 18(6):711-719.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, GUYATT G, GRIFFITH L et al.: Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. (2002) 23(4):570-578.
   PubMed Web of Science ®Google Scholar
• BONE HG, HOSKING D, DEVOGELAER JP et al.: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. (2004) 350(12):1189-1199.
   PubMed Web of Science ®Google Scholar
• DUCY P, ZHANG R, GEOFFROY V, RIDALL AL, KARSENTY G: Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 89(5):747-754.
   PubMed Web of Science ®Google Scholar
• LEE B, THIRUNAVUKKARASU K, ZHOU L et al.: Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat. Genet. (1997) 16(3):307-310.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA K, ZHOU X, KUNKEL G et al.: The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 108(1):17-29.
   PubMed Web of Science ®Google Scholar
• AKUNE T, OHBA S, KAMEKURA S et al.: PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. (2004) 113(6):846-855.
   PubMed Web of Science ®Google Scholar
• MANOLAGAS SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. (2000) 21(2):115-137.
   PubMed Web of Science ®Google Scholar
• HOCK JM, KRISHNAN V, ONYIA JE et al.: Osteoblast apoptosis and bone turnover. J. Bone Miner. Res. (2001) 16(6):975-984.
   PubMed Web of Science ®Google Scholar
• JILKA RL, WEINSTEIN RS, BELLIDO T et al.: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. (1999) 104(4):439-446.
   PubMed Web of Science ®Google Scholar
• GONG YQ, SLEE RB, FUKAI N et al.: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 107 (4):513-523.
   PubMed Web of Science ®Google Scholar
• REID IR, BROWN JP, BURCKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2002) 346(9):653-661.
   PubMed Web of Science ®Google Scholar
• BLACK DM, DELMAS PD, EASTELL R et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. (2007) 356(18):1809-1822.
   PubMed Web of Science ®Google Scholar
• RECKER RR, STAAKESTAD JA, FELSENBERG D: A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fracturesin women with postmenopausal osteoporosis: results of a 3-year trial. J. Bone Miner. Res. (2000) 11(Suppl. 2):S209.
   Google Scholar
• CHRISTIANSEN C, TANKO LB, WARMING L et al.: Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int. (2003) 14(7):609-613.
   PubMed Web of Science ®Google Scholar
• CHESNUT CH, SKAG A, CHRISTIANSEN C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. (2004) 19(8):1241-1249.
   PubMed Web of Science ®Google Scholar
• DELMAS PD, ADAMI S, STRUGALA C et al.: Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. (2006) 54(6):1838-1846.
   PubMed Web of Science ®Google Scholar
• WOO S-B, HELLSTEIN JW, KALMAR JR: Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. (2006) 144(10):753-761.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, ENSRUD KE, WALLACE R et al.: Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet. Gynecol. (2004) 104(3):443-451.
   PubMed Web of Science ®Google Scholar
• REXRODE KM, MANSON JE: Are some types of hormone therapy safer than others?: lessons from the estrogen and thromboembolism risk study. Circulation (2007) 115(7):820-822.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, HARTMANN LC: Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N. Engl. J. Med. (2003) 348(7):618-629.
   PubMed Web of Science ®Google Scholar
• GREY AB, STAPLETON JP, EVANS MC et al.: The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am. J. Med. (1995) 99(6):636-641.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. [Erratum appears in JAMA (1999) 282(22):2124]. JAMA (1999) 282(7):637-645.
   Web of Science ®Google Scholar
• REID IR, EASTELL R, FOGELMAN I et al.: A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch. Intern. Med. (2004) 164(8):871-879.
   PubMed Web of Science ®Google Scholar
• CAULEY JA, NORTON L, LIPPMAN ME et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. [Erratum appears in Breast Cancer Res. Treat. (2001) 67(2):191]. Breast Cancer Res. Treat. (2001) 65(2):125-134.
   Web of Science ®Google Scholar
• BARRETT-CONNOR E, MOSCA L, COLLINS P et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. (2006) 355(2):125-137.
   PubMed Web of Science ®Google Scholar
• KE HZ, QI H, CRAWFORD DT et al.: Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology (2000) 141(4):1338-1344.
   PubMed Web of Science ®Google Scholar
• KE HZ, QI H, CHIDSEY-FRINK KL, CRAWFORD DT, THOMPSON DD: Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J. Bone Miner. Res. (2001) 16(4):765-773.
   PubMed Web of Science ®Google Scholar
• KE HZ, FOLEY GL, SIMMONS HA, SHEN V, THOMPSON DD: Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology (2004) 145(4):1996-2005.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, SIRIS E, CUMMINGS S et al.: Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause (2006) 13(3):377-386.
   PubMed Web of Science ®Google Scholar
• RAGHOW S, OKOLICANY J, SHEN V, VEVERKA K, STEINER M: Effect of toremifene on orchiectomy-induced osteopenia in the male rat. J. Bone Miner. Res. (2004) 19(Suppl. 1):S456.
   Web of Science ®Google Scholar
• KOMM BS, KHARODE YP, BODINE PVN et al.: Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology (2005) 146(9):3999-4008.
   PubMed Web of Science ®Google Scholar
• MODELSKA K, CUMMINGS S: Clinical review 140 – Tibolone for postmenopausal women: systematic review of randomized trials. J. Clin. Endocrinol. Metab. (2002) 87(1):16-23.
   PubMed Web of Science ®Google Scholar
• GALLAGHER JC, BAYLINK DJ, FREEMAN R, MCCLUNG M: Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J. Clin. Endocrinol. Metab. (2001) 86(10):4717-4726.
   PubMed Web of Science ®Google Scholar
• BEARDSWORTH SA, KEARNEY CE, PURDIE DW: Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. Br. J. Obstet. Gynaecol. (1999) 106(7):678-683.
   PubMedGoogle Scholar
• PAVLOV PW, GINSBURG J, KICOVIC PM et al.: Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol. Endocrinol. (1999) 13(4):230-237.
   PubMed Web of Science ®Google Scholar
• STUDD J, ARNALA I, KICOVIC PM et al.: A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet. Gynecol. (1998) 92(4):574-579.
   PubMed Web of Science ®Google Scholar
• ROUX C, PELISSIER C, FECHTENBAUM J, LOISEAU-PERES S, BENHAMOU CL: Randomized, double-masked, 2-year comparison of tibolone with 17 β-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. (2002) 13(3):241-248.
   PubMed Web of Science ®Google Scholar
• GROBBEE DE: LIFT study to continue as planned. BMJ (2005) 331(7520):843-a-.
   PubMedGoogle Scholar
• HOFBAUER LC, KHOSLA S, DUNSTAN CR et al.: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. (2000) 15(1):2-12.
   PubMed Web of Science ®Google Scholar
• MIZUNO A, AMIZUKA N, IRIE K et al.: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. (1998) 247(3):610-615.
   PubMed Web of Science ®Google Scholar
• CUNDY T, HEGDE M, NAOT D et al.: A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. (2002) 11(18):2119-2127.
   PubMed Web of Science ®Google Scholar
• LI J, SAROSI I, YAN XQ et al.: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA (2000) 97(4):1566-1571.
   PubMed Web of Science ®Google Scholar
• KONG YY, YOSHIDA H, SAROSI I et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 397(6717):315-323.
   PubMed Web of Science ®Google Scholar
• BEKKER PJ, HOLLOWAY DL, RASMUSSEN AS et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. (2004) 19(7):1059-1066.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, LEWIECKI EM, COHEN SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2006) 354(8):821-831.
   PubMed Web of Science ®Google Scholar
• WALSH MC, KIM N, KADONO Y et al.: Osteoimmunology: interplay between the immune system and bone metabolism. Ann. Rev. Immunol. (2006) 24:33-63.
   PubMed Web of Science ®Google Scholar
• SORIANO P, MONTGOMERY C, GESKE R, BRADLEY A: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 64(4):693-702.
   PubMed Web of Science ®Google Scholar
• BOYCE BF, YONEDA T, LOWE C, SORIANO P, MUNDY GR: Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. (1992) 90(4):1622-1627.
   PubMed Web of Science ®Google Scholar
• METCALF CA, VAN SCHRAVENDIJK MR, DALGARNO DC, SAWYER TK: Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr. Pharm. Des. (2002) 8(23):2049-2075.
   PubMed Web of Science ®Google Scholar
• VIOLETTE SM, SHAKESPEARE WC, BARTLETT C et al.: A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. Chem. Biol. (2000) 7(3):225-235.
   PubMed Web of Science ®Google Scholar
• MISSBACH M, JESCHKE M, FEYEN J et al.: A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone (1999). 24(5):437-449.
   Google Scholar
• HANNON R, EASTELL R, CLACK G et al.: The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. European Calcified Tissue Society Meeting. Geneva (2005) (Abstract OC042).
   Google Scholar
• FENG X, NOVACK DV, FACCIO R et al.: A Glanzmann'S mutation in β3 integrin specifically impairs osteoclast function. J. Clin. Invest. (2001) 107(9):1137-1144.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP GB, HWANG SM et al.: Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J. Pharmacol. Exp. Ther. (1999) 291(2):612-617.
   PubMed Web of Science ®Google Scholar
• MURPHY MG, CERCHIO K, STOCH SA et al.: Effect of L-000845704, an α-V β-3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. (2005) 90(4):2022-2028.
   PubMed Web of Science ®Google Scholar
• GRAMOUN A, MANOLSON MF, HEERSCHE JNM, TREBEC DP, MAO SY: Vitaxin®, an αv β3 blocking antibody, inhibits osteoclastic resorption by decreasing the number of attached osteoclasts. J. Bone Miner. Res. (2004) 19(Suppl. 1):S154.
   Web of Science ®Google Scholar
• SAFTIG P, HUNZIKER E, WEHMEYER O et al.: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95(23):13453-13458.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP GB, JAMES IE et al.: A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone (2002) 30(5):746-753.
   PubMed Web of Science ®Google Scholar
• KUMAR S, DARE L, VASKO-MOSER JA et al.: A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone (2007) 40(1):122-131.
   PubMed Web of Science ®Google Scholar
• PAPANASTASIOU P, ORTMANN CE, OLSON M, VIGNERON A, TRECHSEL U: Effect of three month treatment with the cathepsin-K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women: evidence for for uncoupling of bone resorption and bone formation. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract 1223).
   Google Scholar
• STOCH SA, MILLER DL, VAN DYCK K et al.: Effect of cathepsin K inhibition on bone resorption markers in healthy postmenopausal women. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract 1224).
   Google Scholar
• ADAMI S, SUPRONIK J, HALA T et al.: Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. American Society for Bone and Mineral research. Philadelphia, PA (2006) (Abstract 1085).
   Google Scholar
• AL-AWQATI Q: Chloride channels of intracellular organelles. Curr. Opin. Cell Biol. (1995) 7(4):504-508.
   PubMed Web of Science ®Google Scholar
• SCHALLER S, HENRIKSEN K, SVEIGAARD C et al.: The chloride channel inhibitor N53736 prevents bone resorption in ovariectomized rats without changing bone formation. J. Bone Miner. Res. (2004) 19(7):1144-1153.
   PubMed Web of Science ®Google Scholar
• KORNAK U, KASPER D, BOSL MR et al.: Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell (2001) 104(2):205-215.
   PubMed Web of Science ®Google Scholar
• FRATTINI A, PANGRAZIO A, SUSANI L et al.: Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J. Bone Miner. Res. (2003) 18(10):1740-1747.
   PubMed Web of Science ®Google Scholar
• HENRIKSEN K, GRAM J, SCHALLER S et al.: Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am. J. Pathol. (2004) 164(5):1537-1545.
   PubMed Web of Science ®Google Scholar
• SORENSEN MG, SCHALLER S, CHRISTIANSEN C et al.: Shifting the balance between bone resorption and bone formation: inhibition of the chloride channel ClC-7 by PB5430 attenuates bone resorption in vitro and in vivo, without affecting bone formation. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract M273).
   Google Scholar
• VAN'T HOF RJ, RALSTON SH: Nitric oxide and bone. Immunology (2001) 103(3):255-261.
   PubMed Web of Science ®Google Scholar
• BRANDI ML, HUKKANEN M, UMEDA T et al.: Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc. Natl. Acad. Sci. USA (1995) 92(7):2954-2958.
   PubMed Web of Science ®Google Scholar
• KASTEN TP, COLLIN-OSDOBY P, PATEL N et al.: Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc. Natl. Acad. Sci. USA (1994) 91(9):3569-3573.
   PubMed Web of Science ®Google Scholar
• WANG FS, WANG CJ, CHEN YJ et al.: Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. Endocrinology (2004) 145(5):2148-2156.
   PubMed Web of Science ®Google Scholar
• AFZAL F, POLAK J, BUTTERY L: Endothelial nitric oxide synthase in the control. of osteoblastic mineralizing activity and bone integrity. J. Pathol. (2004) 202(4):503-510.
   PubMed Web of Science ®Google Scholar
• WIMALAWANSA SJ, DE MARCO G, GANGULA P, YALLAMPALLI C: Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone (1996) 18(4):301-304.
   PubMed Web of Science ®Google Scholar
• WIMALAWANSA SJ, CHAPA MT, YALLAMPALLI C, ZHANG R, SIMMONS DJ: Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone (1997) 21(3):275-280.
   PubMed Web of Science ®Google Scholar
• JAMAL SA, CUMMINGS SR, HAWKER GA: Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J. Bone Miner. Res. (2004) 19(9):1512-1517.
   PubMed Web of Science ®Google Scholar
• AGYIN JK, GUTIERREZ GE, GARRETT RI, MUNDY GR: Nitric oxide donor-bisphosphonate (NO-BP) conjugates as effective anabolic agents for bone. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract M386).
   Google Scholar
• GREENSPAN SL, BONE HG, ETTINGER MP et al.: Effect of recombinant human parathyroid hormone (1 – 84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. (2007) 146(5):326-339.
   PubMed Web of Science ®Google Scholar
• BARBEHENN EK, LURIE P, WOLFE SM: Osteosarcoma risk in rats using PTH 1–34. Trends Endocrinol. Metab. (2001) 12(9):383.
   PubMed Web of Science ®Google Scholar
• MITLAK BH: Parathyroid hormone as a therapeutic agent. Curr. Opin. Pharmacol. (2002) 2(6):694-699.
   PubMed Web of Science ®Google Scholar
• VAHLE JL, SATO M, LONG GG et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol. Pathol. (2002) 30(3):312-321.
   PubMed Web of Science ®Google Scholar
• BLACK DM, GREENSPAN SL, ENSRUD KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349(13):1207-1215.
   PubMed Web of Science ®Google Scholar
• BLACK DM, BOUXSEIN ML, MCGOWAN JA et al.: PTH once weekly increases BMD and is mildly anabolic in postmenopausal osteopenic women: results from the PTH Once Weekly Research (POWR) Study. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract 1158).
   Google Scholar
• COSMAN F, NIEVES J, ZION M et al.: Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. (2005) 353(6):566-575.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO T, SHIRAKI M, HAGINO H, IINUMA H, NAKAMURA T: Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int. (2006) 17(10):1532-1538.
   PubMed Web of Science ®Google Scholar
• GOPALAKRISHNAN V, HWANG S, LOUGHREY H: Administration of ThPTH to humans using Macroflux® transdermal technology results in the rapid delivery of biologically active PTH. J. Bone Miner. Res. (2004) 19(Suppl. 1):S460.
   Web of Science ®Google Scholar
• MIAO DS, TONG XK, CHAN GK et al.: Parathyroid hormone-related peptide stimulates oesteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J. Biol. Chem. (2001) 276(34):32204-32213.
   PubMed Web of Science ®Google Scholar
• FROLIK CA, CAIN RL, SATO M et al.: Comparison of recombinant human PTH(1–34) (LY333334) with a C-terminally substituted analog of human PTH-related protein (1–34) (RS-66271): in vitro activity and in vivo pharmacological effects in rats. J. Bone Miner. Res. (1999) 14(2):163-172.
   PubMed Web of Science ®Google Scholar
• STEWART AF, CAIN RL, BURR DB et al.: Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J. Bone Miner. Res. (2000) 15(8):1517-1525.
   PubMed Web of Science ®Google Scholar
• STEWART AF: PTHrP(1–36) as a skeletal anabolic agent for the treatment of osteoporosis. Bone (1996) 19(4):303-306.
   PubMed Web of Science ®Google Scholar
• HORWITZ MJ, TEDESCO MB, GUNDBERG C, GARCIA-OCANA A, STEWART AF: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. (2003) 88(2):569-575.
   PubMed Web of Science ®Google Scholar
• BROWN EM, GAMBA G, RICCARDI D et al.: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature (1993) 366(6455):575-580.
   PubMed Web of Science ®Google Scholar
• GOWEN M, STROUP GB, DODDS RA et al.: Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. (2000) 105(11):1595-1604.
   PubMed Web of Science ®Google Scholar
• SEUWEN K, HALLEUX C, BOUHELAL R: A new class of non-competitive antagonists of the human calcium-sensing receptor releasing parathyroid hormone (PTH) from parathyroid glands. J. Bone Miner. Res. (2004) 19(Suppl. 1):S196.
   Web of Science ®Google Scholar
• MARIE PJ, AMMANN. P, BOIVIN G, REY C: Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int. (2001) 69(3):121-129.
   PubMed Web of Science ®Google Scholar
• MARIE PJ, HOTT M, MODROWSKI D et al.: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res. (1993) 8(5):607-615.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, SLOSMAN DO, DELMAS PD et al.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis – a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. (2002) 87(5):2060-2066.
   PubMed Web of Science ®Google Scholar
• NIELSEN SP, SLOSMAN D, SORENSEN OH et al.: Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J. Clin. Dens. (1999) 2(4):371-379.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. (2004) 350(5):459-468.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, SEEMAN E, DE VERNEJOUL MC et al.: Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. (2005) 90(5):2816-2822.
   PubMed Web of Science ®Google Scholar
• SEEMAN E, VELLAS B, BENHAMOU C et al.: Strontium ranelate reduces the risk of vertebral and nonvertebral fracturesin women eighty years of age and older. J. Bone Miner. Res. (2006) 21(7):1113-1120.
   PubMed Web of Science ®Google Scholar
• HASSOUN AA, NIPPOLDT TB, TIEGS RD, KHOSLA S: Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am. J. Med. (1997) 103(1):70-73.
   PubMed Web of Science ®Google Scholar
• KHOSLA S, HASSOUN AA, BAKER BK et al.: Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J. Clin. Invest. (1998) 101(10):2165-2173.
   PubMed Web of Science ®Google Scholar
• CONOVER CA, JOHNSTONE EW, TURNER RT et al.: Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm. IGF Res. (2002) 12(3):178-183.
   PubMed Web of Science ®Google Scholar
• BUCHANAN CM, PHILLIPS AR, COOPER GJ: Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet β-cells and enhances insulin secretion. Biochem. J. (2001) 360(Part 2):431-439.
   PubMedGoogle Scholar
• CORNISH J, CALLON KE, BAVA U et al.: Preptin, another peptide product of the pancreatic β-cell, is osteogenic in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. (2007) 292(1):E117-E122.
   PubMed Web of Science ®Google Scholar
• VAN BEZOOIJEN RL, ROELEN BAJ, VISSER A et al.: Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. (2004) 199(6):805-814.
   PubMed Web of Science ®Google Scholar
• WINKLER DG, SUTHERLAND MK, GEOGHEGAN JC et al.: Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. (2003) 22(23):6267-6276.
   PubMed Web of Science ®Google Scholar
• BALEMANS W, EBELING M, PATEL N et al.: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. (2001) 10(5):537-543.
   PubMed Web of Science ®Google Scholar
• BRUNKOW ME, GARDNER JC, VAN NESS J et al.: Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. (2001) 68(3):577-589.
   PubMed Web of Science ®Google Scholar
• WARMINGTON K, MORONY S, SAROSI I: Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood. J. Bone Miner. Res. (2004) 19(Suppl. 1):S56.
   PubMed Web of Science ®Google Scholar
• OMINSKY M, STOUCH B, DOELLGAST G et al.: Administration of sclerostin monoclonal antibodies to female cynomologus monkeys results in increased bone formation, bone mineral density and bone strength. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract 1162).
   Google Scholar
• MUNDY G, GARRETT R, HARRIS S et al.: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286(5446):1946-1949.
   PubMed Web of Science ®Google Scholar
• GARRETT IR, MUNDY GR: The role of statins as potential targets for bone formation. Arthritis Res. (2002) 4(4):237-240.
   PubMedGoogle Scholar
• REID IR, HAGUE W, EMBERSON J et al.: Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet (2001) 357(9255):509-512.
   PubMed Web of Science ®Google Scholar
• BAUER DC, MUNDY GR, JAMAL SA et al.: Use of statins and fracture – results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch. Intern. Med. (2004) 164(2):146-152.
   PubMed Web of Science ®Google Scholar
• REJNMARK L, BUUS NH, VESTERGAARD P et al.: Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J. Bone Miner. Res. (2004) 19(5):737-744.
   PubMed Web of Science ®Google Scholar
• LUPATTELLI G, SCARPONI AM, VAUDO G et al.: Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism (2004) 53(6):744-748.
   PubMed Web of Science ®Google Scholar
• HSIA J, MORSE M, LEVIN V: Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial ISRCTN85429598 – art. no. 7. BMC Musculoskeletal Disord. (2002) 3:7-7.
   PubMedGoogle Scholar
• KUZUYA M, SUZUKI Y, ASAI T et al.: Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly. J. Am. Geriatr. Soc. (2003) 51(11):1677-1678.
   PubMed Web of Science ®Google Scholar
• OXLUND H, ANDREASSEN TT: Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone (2004) 34(4):609-618.
   PubMed Web of Science ®Google Scholar
• TAKEDA S, ELEFTERIOU F, LEVASSEUR R et al.: Leptin regulates bone formation via the sympathetic nervous system. Cell (2002) 111(3):305-317.
   PubMed Web of Science ®Google Scholar
• MOORE RE, SMITH CK II, BAILEY CS, VOELKEL EF, TASHJIAN AH Jr: Characterization of β-adrenergic receptors on rat and human osteoblast-like cells and demonstration that β-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. (1993) 23(3):301-315.
   PubMedGoogle Scholar
• KELLENBERGER S, MULLER K, RICHENER H, BILBE G: Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating β2-adrenergic receptors. Bone (1998) 22(5):471-478.
   PubMed Web of Science ®Google Scholar
• IMAI Y, RODAN SB, RODAN GA: Effects of retinoic acid on alkaline phosphatase messenger ribonucleic acid, catecholamine receptors, and G proteins in ROS 17/2.8 cells. Endocrinology (1988) 122(2):456-463.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI T, TSUBOI T, ARAI M, TOGARI A: Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem. Pharmacol. (2001) 61(5):579-586.
   PubMed Web of Science ®Google Scholar
• MINKOWITZ B, BOSKEY AL, LANE JM, PEARLMAN HS, VIGORITA VJ: Effects of propranolol on bone metabolism in the rat. J. Orthop. Res. (1991) 9(6):869-875.
   PubMed Web of Science ®Google Scholar
• DIETRICH JW, MUNDY GR, RAISZ LG: Inhibition of bone resorption in tissue culture by membrane-stabilizing drugs. Endocrinology (1979) 104(6):1644-1648.
   PubMed Web of Science ®Google Scholar
• PASCO JA, HENRY MJ, SANDERS KM et al.: β-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J. Bone Miner. Res. (2004) 19(1):19-24.
   PubMed Web of Science ®Google Scholar
• SCHLIENGER RG, KRAENZLIN ME, JICK SS, MEIER CR: Use of β-blockers and risk of fractures. JAMA (2004) 292(11):1326-1332.
   PubMed Web of Science ®Google Scholar
• REID IR, GAMBLE GD, GREY AB et al.: β-blocker use, BMD, and fractures in the study of osteoporotic fractures. J. Bone Miner. Res. (2005) 20(4):613-618.
   PubMed Web of Science ®Google Scholar
• LEVASSEUR R, DARGENT-MOLINA P, SABATIER J-P, MARCELLI C, BREART G: β-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. [Erratum appears in J. Am. Geriatr Soc. (2005) 53(6):1085]. J. Am. Geriatr. Soc. (2005) 53(3):550-552.
   Web of Science ®Google Scholar
• REID IR, LUCAS J, WATTIE D et al.: Effects of a β-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J. Clin. Endocrinol. Metab. (2005) 90(9):5212-5216.
   PubMed Web of Science ®Google Scholar
• KATO M, PATEL MS, LEVASSEUR R et al.: Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. (2002) 157(2):303-314.
   PubMed Web of Science ®Google Scholar
• MANI A, RADHAKRISHNAN J, WANG H et al.: LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science (2007) 315(5816):1278-1282.
   PubMed Web of Science ®Google Scholar
• KOKUBU C, HEINZMANN U, KOKUBU T et al.: Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development (2004) 131(21):5469-5480.
   PubMed Web of Science ®Google Scholar
• BABIJ P, ZHAO WG, SMALL C et al.: High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner. Res. (2003) 18(6):960-974.
   PubMed Web of Science ®Google Scholar
• HOLMEN SL, ZYLSTRA CR, MUKHERJEE A et al.: Essential role of β-catenin in postnatal bone acquisition. J. Biol. Chem. (2005) 280(22):21162-21168.
   PubMed Web of Science ®Google Scholar
• KULKARNI NH, ONYIA JE, ZENG Q et al.: Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J. Bone Miner. Res. (2006) 21(6):910-920.
   Google Scholar
• BRÄNDSTRÖM H, MÖRTHBERG A, BERG AL et al.: GSK3 inhibition increases trabecular bone mass in mice. American Society for Bone and Mineral Research Annual Meeting. Philadelphia, PA (2006) (Abstract SA396).
   Google Scholar
• GRISANTI M, NIU QT, FAN W et al.: Dkk-1 inhibition increases bone mineral density in rodents. Amercian Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract 1089).
   Google Scholar
• QUARLES LD: FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am. J. Physiol. (2003) 285(1):E1-E9.
   Web of Science ®Google Scholar
• NAMPEI A, HASHIMOTO J, HAYASHIDA K et al.: Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J. Bone Miner. Metab. (2004) 22(3):176-184.
   PubMed Web of Science ®Google Scholar
• GOWEN LC, PETERSEN DN, MANSOLF AL et al.: Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45). Results in increased bone formation and bone mass. J. Biol. Chem (2003) 278(3):1998-2007.
   PubMed Web of Science ®Google Scholar
• ROWE PSN, KUMAGAI Y, GUTIERREZ G et al.: MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 34(2):303-319.
   PubMed Web of Science ®Google Scholar
• HAYASHIBARA T, HIRAGA T, YI B et al.: A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J. Bone Miner. Res. (2004) 19(3):455-462.
   PubMed Web of Science ®Google Scholar
• LAZAROV M, SHIH M, NEGRON A: AC-100, a fragment of MEPE, promotes fracture healing in a femoral closed fracture model in rats. J. Bone Miner. Res. (2004) 19(Suppl. 1):S456.
   Web of Science ®Google Scholar
• FINKELSTEIN JS, HAYES A, HUNZELMAN JL et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. (2003) 349(13):1216-1226.
   PubMed Web of Science ®Google Scholar
• COSMAN F, NIEVES J, ZION M et al.: Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. (2005) 353(6):566-575.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, SAN MARTIN J, CRANS G, PAVO I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. (2004) 19(5):745-751.
   PubMed Web of Science ®Google Scholar
• GASSER JA, INGOLD P, VENTURIERE A, GREEN JR: Chronic subcutaneous, but not single intravenous dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract F386).
   Google Scholar
• BLACK DM, BILEZIKIAN JP, ENSRUD KE et al.: One year of alendronate after one year of parathyroid hormone (1 – 84) for osteoporosis. N. Engl. J. Med. (2005) 353(6):555-565.
   PubMed Web of Science ®Google Scholar
• EASTELL R, HADJI P, FARRERONS J et al.: Comparison of 3 sequential treatment regimens of teriparatide: final results from the EUROFORS study. American Society for Bone and Mineral Research. Philadelphia, PA (2006) (Abstract 1265).
   Google Scholar

Website

• http://wwwpiribocom/publications/therapeutic/women_health/osteo_hrthtml ANONYMOUS: Women's Health (2004) (Accessed 11 April 2007).
   Google Scholar